Widely used:Recently Viewed
Clear All
$9 Mln
--
0.31
--
0
-49.34 %
--
--
--
-481320
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
| -68.14 | -47.90 | -31.47 | -75.40 | -62.14 | -19.37 | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Purple Biotech (PPBT)
| -43.48 | -64.52 | 2.10 | 388.71 | 18.12 | -70.86 | -26.69 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$9.18 Mln
$0.00 Mln
$0.00 Mln
$7.39 Mln
$0.26 Mln
High
$4.73 - 36.00
1,566,090
NASDAQ: PPBT
Rehovot
https://purple-biotech.com
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that... blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Address: 4 Oppenheimer Street, Rehovot, Israel, 7670104 Read more
The total asset value of Purple Biotech (PPBT) stood at $ 43 Mln as on 30-Jun-24
The share price of Purple Biotech (PPBT) is $4.97 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Purple Biotech (PPBT) has given a return of -62.14% in the last 3 years.
Purple Biotech (PPBT) has a market capitalisation of $ 9 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Purple Biotech (PPBT) is 0.31 times as on 02-Oct-2024, a 88% discount to its peers’ median range of 2.54 times.
Since, TTM earnings of Purple Biotech (PPBT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Purple Biotech (PPBT) and enter the required number of quantities and click on buy to purchase the shares of Purple Biotech (PPBT).
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Address: 4 Oppenheimer Street, Rehovot, Israel, 7670104
The CEO & director of Mr. Gil Efron CPA, M.A.. is Purple Biotech (PPBT), and CFO & Sr. VP is Dr. Michael Schickler Ph.D..
There is no promoter pledging in Purple Biotech (PPBT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
110
|
|
|
85
|
|
|
58
|
|
|
46
|
| Purple Biotech (PPBT) | Ratios |
|---|---|
|
Return on equity(%)
|
-49.34
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Purple Biotech (PPBT) was $0 Mln.
$-0.43
